TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock

PHASE3CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

March 24, 2019

Primary Completion Date

February 28, 2024

Study Completion Date

March 4, 2024

Conditions
Septic ShockAnemiaCancer
Interventions
BIOLOGICAL

Liberal Red blood cell transfusion

"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"

BIOLOGICAL

Restrictive Red blood cell transfusion

Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU

Trial Locations (20)

75005

Hopital Cochin AP-HP, Paris

Unknown

CHU Amiens Picardie Site Sud, Amiens

Hopital Robert Ballanger, Aulnay-sous-Bois

Hopital Avicenne AP-HP, Bobigny

CH sud-Francilien, Corbeil

Hopital Henri Mondor AP-HP, Créteil

CHV André Mignot, Le Chesnay

Salengro, CHRU, Lille

CH Lyon Sud, Lyon

GH Édouard Herriot, Lyon

Institut Paoli Calmettes, Marseille

GH Sud Ile de France, Melun

Bel Air CHR, Metz

Mercy, CHR, Metz

CHU de Nantes, Nantes

La Source, CHR, Orléans

Hopital de La Pitié Salpetriere AP-HP, Paris

Hopital Saint Antoine AP-HP, Paris

Hopital Saint Louis AP-HP, Paris

Gustave Roussy, Villejuif

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03837171 - TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock | Biotech Hunter | Biotech Hunter